NCT07526194

A Study in Healthy Men to Test How Well Different Doses of BI 3821001 Are Tolerated

A Phase I Single-blind, Randomised, Placebo-controlled, Parallel Group Design Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BI 3821001 Administered to Healthy Trial Participants

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3821001 in healthy male trial participants.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	BI 3821001	BI 3821001
DRUG	Placebo	Placebo

Timeline

• Start date: 2026-04-22
• Primary completion: 2026-10-02
• Completion: 2026-10-02
• First posted: 2026-04-13
• Last updated: 2026-04-13

Locations

1 site across 1 country: Germany